ABSTRACT Hormonal, genetic, and environmental factors play major roles in the complex etiology of breast cancer. When treated continuously with 17␤-estradiol (E2), the ACI rat exhibits a genetically conferred propensity to develop mammary cancer. The susceptibility of the ACI rat to E2-induced mammary cancer appears to segregate as an incompletely dominant trait in crosses to the resistant Copenhagen (COP) strain. In both (ACI ϫ COP)F 2 and (COP ϫ ACI)F 2 populations, we find strong evidence for a major genetic determinant of susceptibility to E2-induced mammary cancer on distal rat chromosome 5. Our data are most consistent with a model in which the ACI allele of this locus, termed Emca1 (e strogen-induced m ammary ca ncer 1), acts in an incompletely dominant manner to increase both tumor incidence and tumor multiplicity as well as to reduce tumor latency in these populations. We also find evidence suggestive of a second locus, Emca2, on chromosome 18 in the (ACI ϫ COP)F 2 population. The ACI allele of Emca2 acts in a dominant manner to increase incidence and decrease latency. Together, Emca1 and Emca2 act independently to modify susceptibility to E2-induced mammary cancer.
B
REAST cancer is one of the leading causes of canin determining breast cancer risk (Lichtenstein et al. 2000; Risch 2001; Mack et al. 2002) . cer-related death in women in the United States.
Because estrogens stimulate proliferation of the mamRisk of developing breast cancer is determined by both mary epithelium, the duration of exposure of the breast genetic and environmental factors, as well as by the to estrogens is hypothesized to play a role in breast interactions between genetic and environmental detercancer development. For example, early age at menarminants. A number of genetic factors, such as a germline che and late age at menopause each increase risk of mutation of the BRCA1, BRCA2, or p53 genes, strongly developing breast cancer, presumably by extending the predispose carriers to breast cancer (Tonin 2000; Iau length of time the mammary epithelium is exposed to et al. Dite et al. 2003) . However, only a relatively estrogens (Key et al. 2001; Bernstein 2002) . It has also small percentage of breast cancers, ‫,%01-5ف‬ are due to been suggested that specific polymorphisms in a numinheritance of these highly penetrant mutations. Nonetheber of genes involved in estrogen metabolism may be less, one of the most consistent and significant risk factors correlated with an increased risk of breast cancer (Shull associated with breast cancer development in women not 2002); however, these correlations have been observed in carrying a BRCA1, BRCA2, or p53 mutation is a family some populations (Yim et al. 2001; Kocabas et al. 2002 ; Lee history of breast cancer (Tonin 2000; Dite et al. 2003) . . Thus, genetic factors may play an that of BRCA1 or BRCA2 also play a significant role important role in determining the capacity of estrogens to influence breast cancer risk. In addition to these epidemiological data, clinical trials have provided compel-1 ers specific to simple sequence repeats that are polymorphic cer risk in individuals with identified risk factors and in length between the ACI and COP rat strains were obtained reduces the incidence of contralateral breast cancer that combined estrogen and progestin hormone refor 30 sec, and 72Њ for 1.5 min, with the final cycle followed placement therapy is associated with an increased risk of by incubation at 72Њ for 3 min. For a subset of markers, PCR products were resolved on 3 or 4% agarose gels and visualized breast cancer (Collaborative Group on Hormonal with Cambrex GelStar nucleic acid gel stain (Fisher Scientific, Factors in Breast Cancer 1997; Rossouw et al. 2002) . factors that modulate the action of estrogens in breast
Genotypes were determined at 183 polymorphic markers in cancer development in women. Therefore, we have be-129 (ACI ϫ COP)F 2 rats. For analysis of the (COP ϫ ACI)F 2 population, 137 markers were used. Markers were chosen to gun to explore these issues using the ACI rat, which is achieve a density of ‫1ف‬ marker every 20 cM. However, there highly susceptible to mammary carcinogenesis when the are regions of the genome where this level of marker density circulating level of the naturally occurring estrogen, was not achieved due to a lack of polymorphic markers be-17␤-estradiol (E2), is maintained in the upper physiotween the genetically related ACI and COP strains. Nonethelogic range by exogenous administration (Shull et al. less, there is no region of the genome where the marker 1997 Harvell et al. 2000 Harvell et al. , 2001 Harvell et al. , 2002 . This susdensity is such that a quantitative trait locus (QTL), were it to reside there, would be Ͼ20 cM from the nearest marker.
ceptibility to E2-induced mammary cancer exhibits an formed to normalize the population distribution relative to the mean. For the analysis of the (ACI ϫ COP)F 2 population, evidence for linkage was assessed using experimentwise thresh-MATERIALS AND METHODS old values that were obtained from analysis using 1000 permutations of the phenotypic data (Churchill and Doerge Phenotypic characterization of F 2 progeny : The phenotypi-1994). For this cross, linkage analysis was conducted using all cally defined F 2 progeny utilized in these linkage studies were 129 experimental animals. By contrast, for the (COP ϫ ACI)F 2 generated in crosses between the ACI rat strain and the resispopulation, linkage analysis was initially conducted using the tant COP strain and have been described previously (Shull 43 F 2 animals that exhibited the most highly susceptible (N ϭ et al. 2001) . Briefly, implants containing E2 were placed subcu-21) and the most resistant (N ϭ 22) phenotypes. When an taneously when the rats were 63 Ϯ 4 days of age. Ovary-intact LRS value suggestive of linkage, based on permutation testing females were used for these experiments because ovariectomy (1000 permutations), was obtained, the remaining F 2 animals inhibits the rapid development of E2-induced mammary canwere genotyped at all markers assayed on that chromosome. cers in the ACI rat (Shull et al. 1997) . Beginning 5-7 weeks Only markers on rat chromosomes (RNO) 4, 5, and 18 were later, each animal was examined twice weekly for the presence used to genotype the entire 146 (COP ϫ ACI)F 2 mapping of palpable mammary tumors. Unless necessitated by morbidpopulation. Linkage was then assessed using permutationity, most frequently due to E2-induced pituitary enlargement, derived thresholds obtained from tests performed using data rats were sacrificed when the largest palpable mammary tumor from just these three chromosomes. The confidence interval approximated 2 cm in diameter. The location and size of each for each QTL was estimated using the resampling technique macroscopic mammary tumor were noted at necropsy. All of referred to as bootstrap analysis (Visscher et al. 1996) , which the tumors were classified histologically as carcinoma.
is part of the interval mapping function of MAPMANAGER Determination of genotype at polymorphic genetic markers:
QTX (Manly et al. 2001) . DNA was isolated from the spleen of each F 2 rat using DNeasy spin columns (QIAGEN, Valencia, CA). Oligonucleotide prim-A number of rats from each cross were excluded from the genetic analyses for a variety of reasons. Of the 136 (ACI ϫ ACI)F 2 rats produced and treated with E2, 27 were excluded from the genetic analyses. The majority of these rats, 21 of COP)F 2 rats produced and treated with E2, 7 could not be the 27, were excluded because they were sacrificed following used for the genetic analyses, primarily because these animals Ͻ28 weeks of E2 treatment primarily due to morbidity associwere found dead in their cages or lost their estrogen implants ated with E2-induced pituitary tumorigenesis prior to develduring the course of the experiment. Of the 173 (COP ϫ oping a mammary tumor. Most of the remaining rats were eliminated from the genetic analyses because they were found dead in their cages. Importantly, for both crosses, no rat with a mammary tumor for which tissue was available was excluded from the genetic analyses. Statistical analysis: Survival analysis methods were employed to assess the linkage of a given marker to a locus that controls tumor latency, which is defined as the number of days of E2 treatment prior to the appearance of the first palpable mammary tumor. Specifically, the Breslow test was used to compare tumor latency in the presence of censored observations, that is, animals that were either tumor free at the end of the study or sacrificed due to morbidity from pituitary tumor development prior to developing a mammary tumor. To eliminate spurious evidence for linkage when multiple comparisons are made, linkage was not assessed in this manner for every marker used in the genotypic analysis. Rather, the Breslow test was performed with only one or two markers residing within the intervals in which the LRS values exceeded the threshold for suggestive or significant evidence of linkage. The Cox proportional hazards model was used to examine pairwise interactions between loci with respect to tumor latency. The effect of genotype at specific markers on mammary tumor incidence was assessed using a chi-square test or Fisher's exact test, where appropriate. Linkage of markers on RNOX to a locus modulating mammary tumor development was assessed using the chi-square test. Differences in average mammary tumor multiplicity and pituitary mass among genotypic classes were evaluated using the Wilcoxon rank-sum/Mann-Whitney U-test. Allelic imbalance data were evaluated as described previously using likelihood-based parameter estimation and Bayesian methods (Newton and Lee 2000) . P-values Յ0.05 were considered to be significant.
RESULTS

Mapping
Emca1 to RNO5 in the (ACI ϫ COP)F 2 population: Genetic analysis using 129 (ACI ϫ COP)F 2 progeny yielded significant evidence for linkage of a locus that modulates susceptibility to E2-induced mammary cancer to multiple markers on distal RNO5. An LRS value of 20.2 was obtained at D5Rat30 when the (ACI ϫ COP)F 2 population was evaluated following 175 days of treatment ( Figure 1A ). This LRS value exceeded the permutation-derived thresholds of 10.5 and 17.8 for suggestive and significant evidence of linkage, respectively, with the tumor status following 175 days of treatment treatment in a fashion analogous to the F 2 progeny from the reciprocal (ACI ϫ COP) intercross. When the phenotype. Bootstrap analysis was performed as part of the interval mapping function of MAPMANAGER QTX (COP ϫ ACI)F 2 population was evaluated following 175 days of treatment, the time point giving the peak LRS to provide an estimate of the confidence interval for the location of this QTL. These data indicate that one value in the analysis of the (ACI ϫ COP)F 2 population, an LRS score of 8.3 was obtained at D5Rat53. This LRS or more genetic determinants of susceptibility to E2-induced mammary cancer resides within an interval of value was above the permutation-derived threshold of 5.2 for suggestive evidence of linkage but below the ‫83ف‬ cM on RNO5 defined by markers D5Rat53 and D5Rat57. This locus has been designated Emca1. The threshold of 12.2 for significant evidence of linkage for this phenotype. Interestingly, evaluation of the (COP ϫ genetic models most consistent with the linkage data indicated that the ACI allele of Emca1 (Emca1 ACI ) likely ACI)F 2 population at 189 days of treatment or later yielded significant evidence for linkage. The strongest acts in a recessive or incompletely dominant manner. Consistent with a recessive mode of action for Emca1 ACI , evidence was obtained by evaluation of the (COP ϫ ACI)F 2 population at 189 days of treatment, when linkmammary tumor incidence following 175 days of E2 treatment was significantly greater in rats homozygous age analysis yielded an LRS value of 13.8 in the interval between D5Rat53 and D5Rat95, which exceeded the perfor the ACI allele at D5Rat30 (61%) than in rats heterozygous (22%) or homozygous for the COP allele (17%; mutation-derived thresholds for suggestive and significant evidence of linkage of 5.6 and 12.1, respectively P Ͻ 0.01; Figure 1B ). The incidence of mammary tumors at this time point did not differ between rats het-( Figure 2A ). In the (COP ϫ ACI)F 2 population, the linkage data were most consistent with a recessive or erozygous or homozygous for the COP allele at D5Rat30 (P ϭ 0.34; Figure 1B ).
incompletely dominant mode of action for Emca1. For this cross, the incidence of mammary tumors within 189 There was a highly significant association between mammary tumor latency and genotype at markers within Emca1 days of estrogen treatment was 76% in rats homozygous for the ACI allele at D5Rat53, significantly greater than in the (ACI ϫ COP)F 2 population (P Ͻ 0.01; Figure 1C ). Here, Emca1 ACI appeared to act in an incompletely domieither the 49% in heterozygotes (P Ͻ 0.01) or the 37% in rats homozygous for the COP allele at D5Rat53 (P Ͻ nant manner; median mammary tumor latency was 165 days in rats homozygous for the ACI allele at D5Rat30 0.01; Figure 2B ). Tumor incidence did not differ significantly between rats heterozygous and homozygous for compared to 193 days in rats heterozygous at D5Rat30 and 231 days in rats homozygous for the COP allele at the COP allele at D5Rat53 at this time point (P ϭ 0.37; Figure 2B ).
D5Rat30.
Genetic analysis also suggested that Emca1 is involved In the (COP ϫ ACI)F 2 population, there was a significant association between mammary tumor latency and in determining mammary tumor multiplicity in the (ACI ϫ COP)F 2 population. For analysis of tumor multigenotype at markers within Emca1 (P ϭ 0.03; Figure  2C ). Consistent with the hypothesis that Emca1 acts in plicity data at the time of sacrifice, permutation-derived thresholds for suggestive and significant evidence of an incompletely dominant manner, median mammary tumor latency was 155 days in rats homozygous for the linkage were 10.5 and 17.8, respectively. A peak LRS value of 17.8 was obtained at D5Rat30 when the (ACI ϫ ACI allele at D5Rat53, one of the peak markers in the Emca1 interval in this cross, compared to 190 days in COP)F 2 population was analyzed with respect to tumor multiplicity at the time of sacrifice ( Figure 1D ). For the rats heterozygous at D5Rat53 and 212 days in rats homozygous from the COP allele at D5Rat53. tumor multiplicity phenotype, the confidence interval for Emca1 extended from D5Rat53 to D5Rat205. Here
In the (COP ϫ ACI)F 2 population, which had a significantly lower average tumor number than the (ACI ϫ again, the action of Emca1 ACI seemed most consistent with an incompletely dominant model; tumor-bearing COP)F 2 rats, analysis of tumor multiplicity at sacrifice yielded only suggestive evidence for linkage (LRS ϭ rats homozygous for the ACI allele at D5Rat30 in the Emca1 interval had an average of 3.5 [standard deviation 7.0) between D5Rat53 and D5Rat95 in the Emca1 genetic interval (data not shown; Shull et al. 2001 ). (SD) 2.4] tumors, whereas tumor multiplicity averaged 2.2 (SD 1.6) and 1.6 (SD 1.3) in heterozygotes and COP Emca2 maps to RNO18: Modest evidence for a locus modulating susceptibility to E2-induced mammary carhomozygotes, respectively (P Ͻ 0.02; data not shown).
Emca1 modulates mammary carcinogenesis in the recinogenesis was observed on RNO18 in the (ACI ϫ COP)F 2 population evaluated as a function of whether ciprocal (COP ϫ ACI)F 2 population: Significant evidence for linkage of a QTL with a major effect on mameach rat was tumor negative or positive at 14-day intervals following initiation of E2 treatment. Analysis of the mary tumor development was also observed on RNO5 in a (COP ϫ ACI)F 2 population. A total of 146 progeny (ACI ϫ COP)F 2 females following 189 days of treatment yielded a peak LRS value of 7.4 at the marker D18Rat21 from this cross were genotyped at markers spanning the Emca1 interval on RNO5, and linkage was evaluated as ( Figure 3A ). Although this LRS value fell below the permutation-derived threshold of 10.6 for suggestive a function of whether each F 2 rat was tumor negative or positive at 14-day intervals following initiation of E2 evidence of linkage, we continued to evaluate the impact Mammary Cancer Loci in the ACI Rat The LRS values across RNO5 were derived using tumor status foleffect of genotype at D18Rat21 on mammary tumor incidence lowing 189 days of E2 treatment as a phenotype. (B) The following 189 days of E2 treatment. The 1 indicates that the effect of genotype at D5Rat53 on mammary tumor incidence incidence is significantly different from that in the heterozyfollowing 189 days of E2 treatment. A 1 indicates that the gotes. (C) The effect of genotype at D18Rat21 on mammary incidence is significantly different from that in the ACI homotumor latency and incidence. (᭹) Rats homozygous for the zygotes. (C) The effect of genotype at D5Rat53 on mammary ACI allele at D18Rat21; (᭺) rats heterozygous at D18Rat21; tumor latency and incidence. (᭹) Rats homozygous for the (᭢) rats homozygous for the COP allele at D18Rat21. ACI allele at D5Rat53; (᭺) rats heterozygous at D5Rat53; (᭢) rats homozygous for the COP allele at D5Rat53.
that modulates E2-induced mammary carcinogenesis, the mammary tumor incidence following 189 days of E2 of genotype in this region on mammary carcinogenesis treatment was greater in rats homozygous for the ACI because data obtained from a cross between the ACI and allele at D18Rat21 than in those homozygous for the Brown Norway (BN) rat strains suggest that this genetic COP allele; however, this difference fell short of statistiinterval harbors a locus that modulates E2-induced mamcal significance (P ϭ 0.06; Figure 3B ). By contrast, the mary carcinogenesis in that cross (M. Tochacek, B.
difference in mammary tumor incidence following 189 Schaffer and J. D. Shull, unpublished data). Consistent days of E2 treatment between rats heterozygous for the ACI allele of D18Rat21 and those homozygous for the with the hypothesis that there may be a locus on RNO18 COP allele (55 vs. 21%) did achieve significance (P ϭ E2-induced mammary tumors from (ACI ϫ COP)F 1 rats. These data were normalized to the relative abundance 0.01). No significant difference in mammary tumor incidence was observed at this time point between rats hoof the PCR products amplified for each allele from DNA isolated from the spleen of each animal. The frequency mozygous and heterozygous for the ACI allele at D18Rat21 (44 vs. 55%; P ϭ 0.67).
of allelic imbalance events on these two chromosomes was then compared to that observed at five unlinked backThe Breslow test was employed to assess the effect of genotype on mammary tumor latency. These analyses ground markers on five chromosomes not containing a locus that modulates mammary carcinogenesis. At these revealed a significant association between mammary tumor latency and genotype at D18Rat21 in the (ACI ϫ control markers, 12 allelic imbalances were detected and the number of allelic imbalances varied from 0 to 5 (0 to COP)F 2 population (P ϭ 0.04; Figure 3C ). The median latency was 191 days in rats homozygous for the ACI 24%) per marker (data not shown). Four of these 12 allelic imbalances (33%) represented either loss of the allele at D18Rat21 and 188 days in rats heterozygous at this marker, in contrast to 219 days in the rats homozy-COP resistance allele or gain of the ACI susceptibility allele, a frequency that did not differ significantly (P Ͼ gous for the COP allele at D18Rat21. These observations suggest that the ACI allele of a locus on RNO18 acts 0.05) from that expected in the absence of allelic bias.
In the 21 tumors analyzed, the number of allelic imin a dominant manner to reduce tumor latency and increase incidence in the (ACI ϫ COP)F 2 population.
balance events detected for each of the markers assayed on RNO5 varied from 4 to 9 (19 to 43%; Figure 4 ). FurtherThis locus has been designated Emca2. There was no clear evidence for any interaction between Emca1 and more, 38 of the 51 (75%) allelic imbalance events detected revealed an overabundance of the ACI allele relative to Emca2 with regard to modulation of tumor latency (data not shown). No association between tumor multiplicity the COP allele, suggesting that allelic imbalance events involving either loss of the COP allele or gain of the ACI and genotype at any marker on RNO18 was observed (data not shown).
allele occur more frequently than would be expected if there were no allelic bias in these somatic events (P Ͻ By contrast, there was no evidence for a locus on RNO18 modulating E2-induced mammary cancer devel-0.02). Fourteen of the 21 tumors (67%) displayed allelic imbalance events at one or more markers on RNO5. opment in the (COP ϫ ACI)F 2 population. Regardless of the phenotype used to analyze this cross, LRS values Significantly, 7 of 21 tumors (33%), displayed regions of significant allelic imbalance-either loss of the COP on RNO18 fell below the permutation-derived threshold for evidence suggestive of linkage (data not shown).
resistance allele or gain of the ACI susceptibility allelethat spanned two or more adjacent markers in the Emca1 The highest LRS value, 4.8 at D18Rat43, was obtained when the (COP ϫ ACI)F 2 population was evaluated interval. These data were evaluated for statistical significance using previously described methods (Newton and following 189 days of treatment (data not shown). This value fell below the threshold of 5.6 for suggestive evi- Lee 2000) . When a conditional hypothesis testing method was used to evaluate the data generated for RNO5, evidence of linkage with this phenotype. Likewise, there was no observed association between tumor latency and dence of excessive allelic imbalance fell short of the threshold of statistical significance (P ϭ 0.14). However, likeligenotype at D18Rat21 (P ϭ 0.67). Thus, Emca2 did not have any perceptible effect on E2-induced mammary hood analysis did suggest that there was excessive allelic imbalance in the Emca1 interval. Whereas the neutral carcinogenesis in the (COP ϫ ACI)F 2 population.
Allelic imbalances in Emca1 and Emca2 intervals: Bebackground loci were imbalanced 20% of the time, the apparent hot spot for allelic imbalance on RNO5 was cause the Emca1 and Emca2 intervals in the rat are syntenic with regions of the human genome that frequently imbalanced 50% of the time. This likelihood analysis yielded a Bayes factor of 1.4, providing evidence for excesshow somatic deletions in human breast cancer, we hypothesized that Emca1 and Emca2 may be inactivated by sive allelic imbalances in the Emca1 interval on RNO5. The number of allelic imbalance events detected for somatic genetic events, such as loss of heterozygosity, during E2-induced mammary carcinogenesis (Callahan each of the markers assayed on RNO18 varied from 4 to 11 (19 to 52%; Figure 5 ). Twenty-two of the 30 (73%) et al. 1992; Bieche and Lidereau 1995; Eiriksdottir et al. 1995; Weith et al. 1996; Tirkkonen et al. 1998;  allelic imbalance events detected represented either loss of the COP resistance allele or gain of the susceptible An et al. 1999; Loveday et al. 2000; Richard et al. 2000) . Frequent somatic loss would suggest that these Emca ACI allele. This frequency was not significantly different from what would be expected in the absence of allelic loci act as classical tumor suppressor genes and would allow fine-structure genetic mapping by deletion analybias for somatic losses (P Ͼ 0.05). The majority of tumors, 20 of 21 (95%), had allelic imbalance events insis. Therefore, we screened a panel of 21 E2-induced mammary tumors from (ACI ϫ COP)F 1 females for alvolving one or more markers on RNO18. Furthermore, 4 of 21 tumors (19%) displayed regions of significant lelic imbalances at markers on RNO5 and 18. For these analyses, the relative abundance of the PCR products allelic imbalance-either loss of the COP resistance allele or gain of the ACI susceptibility allele-spanning amplified from the ACI and COP alleles at markers on RNO5 and 18 were quantitated from DNA isolated from two or more adjacent markers in the Emca2 interval. Analysis of these data by conditional hypothesis testing and tumor latency (data not shown). No evidence for these suggestive loci was observed in the (COP ϫ ACI)F 2 yielded evidence for excessive allelic imbalance that fell short of statistical significance (P ϭ 0.10). However, population.
Composite interval mapping was also employed to likelihood analysis of the observation that the neutral background loci were imbalanced just 20% of the time, determine whether the effects of Emca1 limited our power to detect other loci controlling susceptibility to whereas the apparent hot spot for allelic imbalance on RNO18 was imbalanced 70% of the time, yielded a Bayes E2-induced mammary carcinogenesis. For this analysis, regression and interval mapping were performed followfactor of 4.3, providing evidence of excessive allelic imbalance in the Emca2 interval on RNO18.
ing fixing the peak marker within the Emca1 interval, D5Rat30, as background. This analysis revealed no sigAnalysis of linkage of mammary tumor phenotypes with markers outside of RNO5 and 18: Linkage analysis nificant evidence that loci unlinked to Emca1 modulate mammary tumor susceptibility in this cross. However, revealed no significant evidence for linkage of a locus modulating the incidence of E2-induced mammary tusuggestive evidence for a QTL linked to D6Mit10 that modulates tumor multiplicity in this cross remained, as mor development or mammary tumor multiplicity to any other marker examined in either the (ACI ϫ COP)F 2 the LRS value of 14.8 associated with this marker was still suggestive after fixing Emca1 as background. or the (COP ϫ ACI)F 2 populations. However, suggestive evidence for a QTL on RNO3 (D3Rat41; LRS ϭ 11.9;
The effect of genotype at a number of specific additional markers on mammary tumor latency was also phenotype was the tumor incidence after 161 days of treatment), RNO6 (D6Mit10; LRS ϭ 15.0; phenotype was the assessed. Specifically, we tested the hypothesis that loci known to modulate the ability of the estrogen diethylstiltumor number at sacrifice), and RNO13 (D13Rat33; LRS ϭ 11.1; phenotype was the tumor incidence after bestrol (DES) to induce proliferation of the prolactinproducing lactotrophs in the pituitary would also modu-203 days of treatment) was obtained following analysis of the entire (ACI ϫ COP)F 2 population, indicating that late susceptibility to E2-induced mammary cancer. The ACI and COP rat strains differ in their sensitivity to these regions of the genome may contain loci that modulate E2-induced mammary carcinogenesis (data not DES-induced lactotroph hyperplasia and associated hyperprolactinemia, commonly referred to as pituitary tushown). The association between genotype at D6Mit10 and tumor multiplicity at sacrifice was confirmed using mors (Spady et al. 1999) . Genetic analysis of (ACI ϫ COP)F 2 and (COP ϫ ACI)F 2 males, siblings of the fenonparametric statistical analysis (P Ͻ 0.01, data not shown). However, the Breslow test failed to reveal a clear males described here, indicates that sensitivity to DESinduced pituitary tumorigenesis is controlled by six geassociation between genotype at markers in these intervals COP)F 2 and (COP ϫ ACI)F 2 males also identified two suggestive Ept loci that may influence sensitivity to DESinduced pituitary tumorigenesis. One suggestive Ept locus was associated with D4Rat196. The other suggestive Ept locus was linked to D5Rat95, which resides within the Emca1 interval. Thus, of all the significant and suggestive QTL that regulate sensitivity to DES-induced pituitary tumorigenesis in the (ACI ϫ COP)F 2 and (COP ϫ ACI)F 2 males, just one, the suggestive Ept locus on RNO5, colocalizes with a locus influencing susceptibility to E2-induced mammary carcinogenesis in the (ACI ϫ COP)F 2 females. The effect of the Ept loci on E2-induced mammary carcinogenesis was not evaluated in the entire (COP ϫ ACI)F 2 population because only a subset of this population was genotyped at markers in the Ept intervals.
Genetic analysis of E2-induced pituitary tumorigenesis in (ACI ϫ COP) and (COP ϫ ACI) F 2 females: To assess the effect of each Ept locus on pituitary tumorigenesis in the (ACI ϫ COP)F 2 population, LRS values were evaluated across RNO1, -3, -6, and -10 as a function of log 10 transformed pituitary mass. No effect of Ept1, Ept2, Ept6, Ept9, or Ept13 on pituitary mass could be detected in these crosses (data not shown). However, it should be noted that the power to detect loci modulating quantitative differences in pituitary mass, which is strongly influenced by the length of estrogen treatment (Wiklund et al. 1981) , is limited in the (ACI ϫ COP)F 2 females because these rats were sacrificed following varying for this marker, the average pituitary mass was 84.1 mg, significantly greater than that observed in the ACI homozygotes (P ϭ 0.04). In rats homozygous for the COP netic loci: Ept10 (estrogen-induced pituitary tumor) and Ept13 on RNO1, Ept2 and Ept6 on RNO3, Ept1 on RNO6, allele at D1Rat75 the average pituitary mass was 113.6 mg, significantly greater than that observed in rats either and Ept9 on RNO10 (T. E. Strecker and J. D. Shull, unpublished data). The region encompassing Ept1 on heterozygous (P ϭ 0.04) or homozygous for the ACI allele at D1Rat75 (P Ͻ 0.01; Figure 6B ). Importantly, RNO6 is unlinked to D6Mit10, the peak marker associated with the suggestive locus on RNO6 that may modugenotype in the Ept10 interval had no impact on the duration of survival following initiation of E2 treatment late mammary tumor multiplicity. Thus, the linkage analyses described above indicated that these six signifi-(P ϭ 0.92). These data suggest that the COP allele of Ept10 acts in an incompletely dominant manner to cant Ept loci had no effect on E2-induced mammary tumor incidence or on multiplicity in the (ACI ϫ COP)F 2 increase pituitary mass. These data are similar to those obtained in the analysis of the (ACI ϫ COP)F 2 and cross. Likewise, genotype at each of these Ept loci had no effect on mammary tumor latency in (ACI ϫ COP)F 2 (COP ϫ ACI)F 2 males, which also indicates that the COP allele of Ept10 confers sensitivity to DES pituitary females (Table 1) . Linkage analysis using the (ACI ϫ A/A, homozygous for the ACI allele at the indicated marker; A/C, heterozygous at the indicated marker; C/C, homozygous for the COP allele at the indicated marker. tumorigenesis (T. E. Strecker and J. D. Shull, unpubmanner to increase tumor incidence and multiplicity lished data). Once again, the (COP ϫ ACI)F 2 females and to decrease tumor latency. The region of RNO5 were not evaluated in an analogous manner because encompassing Emca1 also contains a determinant of susonly a subset of this population was genotyped at markceptibility to E2-induced mammary carcinogenesis in ers in the Ept intervals.
crosses between the ACI and unrelated BN rat strain (M. Linkage analysis revealed no significant evidence for Tochacek, B. Schaffer and J. D. Shull, unpublished linkage of a locus modulating E2-induced pituitary tudata). morigenesis to any other marker examined in the entire
The region of RNO5 containing Emca1 is syntenic to (ACI ϫ COP)F 2 female population, including those human chromosomes 1p and 9p (http:/ /www.ensembl. within Emca1 (LRS ϭ 4.2) and Emca2 (LRS ϭ 1.4; data org/), two regions of the human genome that have been not shown). Genetic analysis of pituitary tumorigenesis implicated in breast cancer etiology. Loss of heterozyin the entire (COP ϫ ACI)F 2 female population was gosity (LOH) at chromosome 1p markers, one of the assessed exclusively in the Emca1 and Emca2 intervals; most common genetic aberrations observed in breast LRS values in these intervals did not exceed 3.7 (data cancer, is observed in nearly 40% of breast tumors (Calnot shown). et al. 1996) . Likewise, LOH is also observed at human (ACI ϫ COP)F 2 or (COP ϫ ACI)F 2 females. chromosome 9p markers in nearly 40% of breast cancers (Eiriksdottir et al. 1995; Tirkkonen et al. 1998; An et al. 1999) . Interestingly, we observe allelic imbalances DISCUSSION suggestive of LOH within Emca1 in a significant fraction of E2-induced mammary cancers in (ACI ϫ COP)F 1 rats. The data presented in this article significantly enThe Cdkn2a tumor suppressor gene maps within the Emca1 hance our understanding of the genetic bases of suscepinterval on RNO5 (Laes et al. 1998) . Cdkn2a encodes tibility to mammary cancer in a novel animal model two proteins, p16 Cdkn2a and p19 Arf (Quelle et al. 1995) . in which mammary cancer is induced by continuous Interestingly, a particular germline mutation in Cdkn2a treatment with E2. Here, we map Emca1, which moduhas been demonstrated to predispose women to breast lates E2-induced mammary tumor incidence, multipliccancer (Borg et al. 2000) . Moreover, a large fraction of ity, and latency, to a region of ‫83ف‬ cM on RNO5. Emca1 human breast cancers do not express detectable levels segregates in crosses between the ACI and COP strains of p16 Cdkn2a (Geradts and Wilson 1996) . We have obregardless of the parental orientation used to generate served that both the focal regions of atypical hyperplasia the F 1 rats. In these crosses, the ACI allele of Emca1 appears to act in a recessive or incompletely dominant and the mammary carcinoma that develop in E2-treated F 1 progeny was reversed. One possible explanation for this difference with regard to genetic mapping may be the subtle phenotypic differences observed between the (ACI ϫ COP)F 2 and (COP ϫ ACI)F 2 populations; although there is no difference in the incidence of E2-induced mammary carcinogenesis between the two populations, there is a significant difference between the two populations with respect to the mean latency: 193 (SD 50) days in the (ACI ϫ COP)F 2 rats vs. 157 (SD 44) days in the (COP ϫ ACI)F 2 rats (Shull et al. 2001) . Similar differences in latency were observed in the (ACI ϫ COP)F 1 and (COP ϫ ACI)F 1 rats [207 (SD 59) vs. 163 (SD 32)], suggesting that the parental orientation of the cross may have a significant impact on susceptibility to E2-induced mammary carcinogenesis. The failure to detect Emca2 in the (COP ϫ ACI)F 2 cross is not due to a lack of power because of small sample size; 146 rats from the (COP ϫ ACI)F 2 population were used for genetic analysis whereas 129 rats from the (ACI ϫ COP)F 2 population were studied. The region of RNO18 containing Emca2 is syntenic to human chromosome 5q (http://www.ensembl.org/), which is reported to exhibit LOH in ‫%52ف‬ of human breast cancers (Loveday et al. 2000; Richard et al. 2000) . Interesting candidates in the Emca2 interval include genes involved in breast cancer development or estrogen metabolism, such as fibroblast growth factor 1, glucocorticoid receptor, 17␤-hydroxysteroid dehydrogenase type IV, and adenomatous polyposis coli (http://www.ensembl.org/). As was The COP rat has been used in several genetic studies from that in the ACI homozygotes; 2 indicates that the pituitary mass is significantly different from that in the COP homozyof susceptibility to mammary cancer induction (Isaacs gotes. 1986 (Isaacs gotes. , 1988 Korkola et al. 1997; Shepel et al. 1998; Harvell et al. 2000; Shull et al. 2001) . In crosses between the highly susceptible Wistar-Furth (WF) strain ACI rats exhibit markedly reduced expression of p16
Cdkn2a
, and the resistant COP strain, four loci that determine suggesting that loss of p16 Cdkn2a expression may be an susceptibility to 7,12-dimethylbenz[a]anthracene (DMBA)-early and contributory event in E2-induced mammary induced mammary cancer have been mapped to RNO1, carcinogenesis (B. Xie and J. D. Shull, unpublished -2, -7, and -8 (Hsu et al. 1994; Shepel et al. 1998) . Data data). Because of these similarities between human from the present genetic study indicate that none of breast cancer and the ACI rat model of E2-induced these loci determine susceptibility to E2-induced mammammary carcinogenesis, we consider Cdkn2a to be an mary cancer in reciprocal crosses between the ACI and attractive Emca1 candidate. Other interesting candidates COP strains. Emca1 maps to the same region of RNO5 as known to play a role in breast cancer in humans that
Mcs5, a determinant of susceptibility to DMBA-induced map within the Emca1 interval include Jak1 and c-Jun mammary cancer identified in a cross between the sus- (Smith et al. 1999; Ludes-Meyers et al. 2001 ; Welcsh ceptible WF and resistant Wistar-Kyoto rat strains (Lan et al. 2002 (Lan et al. ). et al. 2001 . Whereas Emca1 is a strong modifier of sus-A second locus, Emca2, has been mapped to a 20-cM ceptibility to E2-induced mammary cancer in ACI ϫ region of RNO18. The ACI allele of Emca2 appears to COP crosses, Mcs5 did not modify susceptibility to act in a dominant manner to increase tumor incidence DMBA-induced mammary cancer in crosses between the and decrease tumor latency. Surprisingly, Emca2 was WF and resistant COP strains (Shepel et al. 1998) . These mapped in the (ACI ϫ COP)F 2 population but not in data suggest significant differences with regard to the the (COP ϫ ACI)F 2 rats, which were generated in crosses genetic bases of susceptibility in the E2-and DMBAinduced mammary cancer models. Consistent with this in which the parental orientation used to generate the hypothesis, the ACI rat strain has been demonstrated to appear to be largely distinct genetically from those controlling susceptibility to E2-induced mammary carcinogenesis. be resistant to DMBA-induced mammary tumorigenesis
The hypothesis that distinct genes control susceptibil-(Isaacs 1988), but highly susceptible to E2-induced ity to estrogen-induced mammary carcinogenesis and mammary cancer (Shull et al. 1997 (Shull et al. , 2001 sensitivity to estrogen-induced pituitary tumorigenesis al. 2000, 2001, 2002) . Interestingly, the Emca1 interval is supported by the fact that certain experimental condion RNO5 is syntenic to a region of mouse chromosome tions inhibit the rapid development of E2-induced mam-4 containing Mmtg2, a locus that modulated mouse polymary cancer but have no impact on sensitivity to E2-oma middle T-antigen-induced mammary tumor mass induced pituitary tumorigenesis (Shull et al. 1997 ; but not latency in a cross between the I/LnJ and FVB / Harvell et al. 2001) . For example, ovariectomy inhib-N-TgN(MMTVPyMT) 634Mul strain (Le Voyer et al. 2001) . ited the rapid development of mammary cancers in ACI It has been postulated that E2-induced mammary carfemales treated with E2 for 20 weeks, but had no impact cinogenesis is dependent upon E2-induced pituitary tuon sensitivity to E2-induced pituitary tumorigenesis in morigenesis and associated hyperprolactinemia (Stone these same rats (Shull et al. 1997) . Likewise, dietary et al. 1979; Sumi et al. 1983; Ito et al. 1984) . However, energy restriction reduced mammary tumor incidence we have previously noted that in the (ACI ϫ COP)F 2 and tumor number but had no impact on E2-induced and (COP ϫ ACI)F 2 females used for genetic analysis of pituitary tumorigenesis or associated hyperprolactinsusceptibility to E2-induced mammary carcinogenesis, emia in ACI females treated with E2 for 12-31 weeks there was no correlation between pituitary mass, which (Harvell et al. 2001) . Thus, in experiments in which correlates with circulating prolactin levels, and susceptigender, the estrogen used, and, in the case of the ovaribility to E2-induced mammary carcinogenesis (Shull ectomy study, the length of treatment, are constant, et al. 2001) . Furthermore, genetic analysis of these femodulation of experimental conditions reveals that susmales, in conjuction with a genetic analysis of the sensiceptibility to E2-induced mammary carcinogenesis and tivity to DES-induced pituitary tumorigenesis in male sensitivity to E2-induced pituitary tumorigenesis are offspring from these same crosses, is not consistent with likely to be largely genetically distinct. this hypothesis. If E2-induced mammary carcinogenesis
The mapping of Emca1 and Emca2 significantly exwere dependent upon pituitary tumorigenesis and hypands our understanding of estrogen action in the mamperprolactinemia, we would anticipate that Emca1 and mary gland and genetic susceptibility to mammary carciEmca2, which modulate mammary carcinogenesis, would nogenesis. Furthermore, this linkage analysis contributes also regulate pituitary tumorigenesis. However, neither significantly to our overall understanding of genetic conlocus has any discernible effect on pituitary mass in the trol of estrogen action. It is becoming clear that genetic (ACI ϫ COP)F 2 and (COP ϫ ACI)F 2 females.
factors play a significant role in controlling the responses In (ACI ϫ COP)F 2 and (COP ϫ ACI)F 2 males, sensitivof many tissues to estrogens. In addition to Emca1 and ity to DES-induced pituitary tumorigenesis is controlled Emca2, loci have been mapped that regulate E2-induced by six genetic loci: Ept10 and Ept13 on RNO1, Ept2 and eosinophil infiltration into the uterus in the mouse Ept6 on RNO3, Ept1 on RNO6, and Ept9 on RNO10 (T. E. (Griffith et al. 1997; Roper et al. 1999) as well as DESStrecker and J. D. Shull, unpublished data). Just one induced pituitary tumorigenesis (Wendell and Gorski of these loci, Ept10, was found to modulate sensitivity 1997; T. E. Strecker and J. D. Shull, unpublished to E2-induced pituitary tumorigenesis in the (ACI ϫ data), susceptibility to E2-induced uterine inflammation COP)F 2 females. The observed differences between the and pyometra (K. A. Gould and J. D. Shull, unpub-(ACI ϫ COP)F 2 males and females with regard to the lished data), and sensitivity to DES-induced thymic atroeffect of the Ept loci on pituitary tumorigenesis may be phy (K. A. Gould and J. D. Shull, unpublished data) due to the fact that the power to detect these loci is in the rat. The loci controlling these estrogen-induced limited because females from this cross, unlike the phenotypes map to many distinct regions of the gemales, were not sacrificed at a defined time point. Alternome, suggesting that a substantial number of genes natively, differences in gender, the estrogen used, and may control estrogen action in these tissues. the length of treatment may also affect the impact of In summary, we have mapped two loci that modify the Ept loci on pituitary tumorigenesis. Importantly, there susceptibility to E2-induced mammary cancer in genetic was no evidence that any of the Ept loci had any effect crosses between the highly susceptible ACI rat strain on E2-induced mammary carcinogenesis in the (ACI ϫ and the genetically related but resistant COP strain. On COP)F 2 females. Weak evidence, based on an LRS value the basis of the fact that genotype at markers linked to that just crossed the permutation-derived threshold for Brca1 and p53, which reside on RNO10, as well as to suggestive linkage, was obtained for a locus on RNO5 in Brca2, which resides on RNO12, showed no correlation the same region as Emca1 that modulates sensitivity to with any of the mammary tumor phenotypes assessed DES-induced pituitary tumorigenesis in the (ACI ϫ in these crosses, we can exclude these genes as determi-COP)F 2 and (COP ϫ ACI)F 2 males. Thus loci regulating nants of the susceptibility of the ACI rat to E2-induced mammary cancer. Identification of the genes within estrogen-induced pituitary tumorigenesis in these crosses lobuloalveolar hyperplasia and susceptibility to estrogen-induced Emca1 and Emca2 that confer susceptibility should promammary cancers. Proc. Natl. Acad. Sci. USA 97: 2779-2784. vide invaluable insights into the mechanisms through ment.
